Ovid Therapeutics Inc. (NasdaqCM: OVID)
Health Care · Biotechnology · US
$2.16
-8.86% today · +38.5% 1Y
Ovid Therapeutics Inc. (NasdaqCM: OVID) operates in the Biotechnology industry within the Health Care sector. The company is valued at $421.84M and employs 23 people.
Over the last twelve months the share price has gained 38.5%, trading between 1.18 and 3.11.
Tweenvest scores Ovid Therapeutics Inc. across four factors: quality 39/100, value 72/100, growth 100/100. Its strongest factor is growth.
OVID price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $421.84M
- Revenue (TTM)
- $1.58M
- P/E
- —
- EPS
- -0.28
- Dividend yield
- —
- Beta (5Y)
- 0.23
- 52-week high
- $3.11
- 52-week low
- $1.18
- Avg volume (3M)
- —
- Shares outstanding
- 195.30M
- Employees
- 23
- Next earnings
- —
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical firm dedicated to creating significant treatments for individuals and families impacted by neurological disorders across the United States. The company's robust pipeline features several key therapeutic candidates: OV101, a drug candidate currently undergoing Phase 2A clinical trials for Fragile X syndrome; OV329, an inhibitor targeting GABA aminotransferase, aimed at managing seizures linked to tuberous sclerosis complex and infantile spasms; and OV350, a small molecule developed to address various forms of epilepsy. Beyond these, Ovid is also advancing OV882, a short hairpin RNA (shRNA) gene therapy designed to treat Angelman syndrome, and OV815, targeting neurological disorders connected to the kinesin-family of proteins. To bolster its research and development efforts, Ovid maintains licensing and collaborative agreements with prominent entities such as Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Marinus Pharmaceuticals, Inc. Established in 2014, the company's corporate headquarters are situated in New York, New York.
- ISIN
- US6904691010
- Founded
- 2014
- Listed since
- May 5, 2017
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Assembly Biosciences, Inc.NasdaqGS: ASMB | $431.44M | $21.19 | +5.11% |
| ACRO Biomedical Co., Ltd.TPEX: 6748 | $429.72M | NT$194.50 | -8.69% |
| Prothena Corporation plcNasdaqGS: PRTA | $428.66M | $8.35 | -5.54% |
| MapLight Therapeutics, Inc.NasdaqGS: MPLT | $427.93M | $7.70 | -12.80% |
| YD Bio LimitedNasdaqGM: YDES | $419.32M | $5.92 | -12.04% |
| Edding Genor Group Holdings LimitedSEHK: 6998 | $418.87M | HK$1.65 | -3.24% |
| Beijing Kawin Technology Share-Holding Co., Ltd.SHSE: 688687 | $412.63M | CN¥16.49 | -10.04% |
| Altimmune, Inc.NasdaqGM: ALT | $412.38M | $2.12 | -2.30% |
Figures last refreshed Oct 18, 2026.